T. Rowe Price Associates’s Rhythm Pharmaceuticals RYTM Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $144M | Buy |
1,654,876
+94,029
| +6% | +$9.14M | 0.02% | 535 |
|
|
2025
Q4 | $167M | Buy |
1,560,847
+160,950
| +11% | +$17.1M | 0.02% | 513 |
|
|
2025
Q3 | $141M | Buy |
1,399,897
+58,505
| +4% | +$5.43M | 0.02% | 543 |
|
|
2025
Q2 | $84.8M | Buy |
1,341,392
+142,339
| +12% | +$8.72M | 0.01% | 608 |
|
|
2025
Q1 | $63.5M | Buy |
1,199,053
+513,901
| +75% | +$28.5M | 0.01% | 651 |
|
|
2024
Q4 | $38.4M | Buy |
685,152
+134,622
| +24% | +$7.44M | ﹤0.01% | 829 |
|
|
2024
Q3 | $28.8M | Buy |
550,530
+24,588
| +5% | +$1.18M | ﹤0.01% | 904 |
|
|
2024
Q2 | $21.6M | Buy |
525,942
+44,409
| +9% | +$1.77M | ﹤0.01% | 950 |
|
|
2024
Q1 | $20.9M | Sell |
481,533
-90,764
| -16% | -$3.97M | ﹤0.01% | 968 |
|
|
2023
Q4 | $26.3M | Buy |
572,297
+361,945
| +172% | +$11.4M | ﹤0.01% | 884 |
|
|
2023
Q3 | $4.82M | Sell |
210,352
-12,885
| -6% | -$289K | ﹤0.01% | 1189 |
|
|
2023
Q2 | $3.68M | Buy |
223,237
+51,657
| +30% | +$932K | ﹤0.01% | 1271 |
|
|
2023
Q1 | $3.06M | Buy |
171,580
+157,380
| +1,108% | +$3.95M | ﹤0.01% | 1320 |
|
|
2022
Q4 | $414K | Sell |
14,200
-2,100
| -13% | -$54K | ﹤0.01% | 2222 |
|
|
2022
Q3 | $400K | Buy |
+16,300
| New | +$303K | ﹤0.01% | 2240 |
|
|
2022
Q2 | – | Sell |
-12,900
| Closed | -$149K | – | 3009 |
|
|
2022
Q1 | $149K | Buy |
+12,900
| New | +$113K | ﹤0.01% | 2773 |
|
|
2021
Q4 | – | Sell |
-16,712
| Closed | -$218K | – | 3032 |
|
|
2021
Q3 | $218K | Hold |
16,712
| – | – | ﹤0.01% | 2693 |
|
|
2021
Q2 | $327K | Buy |
16,712
+1,247
| +8% | +$25.9K | ﹤0.01% | 2566 |
|
|
2021
Q1 | $329K | Buy |
15,465
+195
| +1% | +$5.66K | ﹤0.01% | 2531 |
|
|
2020
Q4 | $454K | Buy |
+15,270
| New | +$388K | ﹤0.01% | 2282 |
|
|
2020
Q1 | – | Sell |
-836,985
| Closed | -$19.2M | – | 2554 |
|
|
2019
Q4 | $19.2M | Sell |
836,985
-19,339
| -2% | -$430K | ﹤0.01% | 1196 |
|
|
2019
Q3 | $18.5M | Sell |
856,324
-215,717
| -20% | -$4.63M | ﹤0.01% | 1174 |
|
|
2019
Q2 | $23.6M | Buy |
1,072,041
+64,625
| +6% | +$1.63M | ﹤0.01% | 1136 |
|
|
2019
Q1 | $27.6M | Buy |
1,007,416
+214,142
| +27% | +$6.15M | ﹤0.01% | 1075 |
|
|
2018
Q4 | $21.3M | Buy |
793,274
+3,259
| +0.4% | +$90.1K | ﹤0.01% | 1122 |
|
|
2018
Q3 | $23M | Buy |
790,015
+236,130
| +43% | +$7.46M | ﹤0.01% | 1177 |
|
|
2018
Q2 | $17.3M | Buy |
553,885
+130,836
| +31% | +$3.58M | ﹤0.01% | 1246 |
|
|
2018
Q1 | $8.42M | Buy |
423,049
+118,922
| +39% | +$3.16M | ﹤0.01% | 1365 |
|
|
2017
Q4 | $8.84M | Buy |
+304,127
| New | +$8.04M | ﹤0.01% | 1359 |
|
Other funds holding RYTM
RCM
BBA
VPM
VCM
PA
T. Rowe Price Associates's RYTM Position: Q1 2026 in Review
T. Rowe Price Associates increased its Rhythm Pharmaceuticals (RYTM) stake by 6% in Q1 2026, buying an estimated $9.14M and bringing the position to 1,654,876 shares worth $144M. The position accounts for 0.02% of the portfolio, ranked #535.
T. Rowe Price Associates first reported a position in RYTM in Q4 2017 and has held it in 29 quarters since. The position peaked at $167M in Q4 2025. 285 funds tracked by Wall St. Rank hold RYTM as of Q1 2026.
- T. Rowe Price Associates held 1,654,876 shares of Rhythm Pharmaceuticals worth $144M as of Q1 2026.
- T. Rowe Price Associates bought 94,029 Rhythm Pharmaceuticals shares in Q1 2026, an estimated $9.14M.
- Rhythm Pharmaceuticals made up 0.02% of T. Rowe Price Associates's portfolio in Q1 2026, its #535 holding.
- T. Rowe Price Associates first reported a position in Rhythm Pharmaceuticals in Q4 2017 and has held it in 29 quarters since.
- T. Rowe Price Associates's Rhythm Pharmaceuticals position peaked at $167M in Q4 2025.
- 285 funds tracked by Wall St. Rank held Rhythm Pharmaceuticals as of Q1 2026.
Based on T. Rowe Price Associates's 13F filing for Q1 2026, filed 15 May 2026.